Harvard Bioscience slumps after weak revenue forecast

Harvard Bioscience

12/03/2025 13:02

Updates

** Shares of Harvard Bioscience HBIO.O down 21.3% at 60 cents premarket

** Co expects Q1 revenue between $19 million and $21 million, below analysts' estimate of $22.95 million - data compiled by LSEG

** The company is also exploring alternative capital sources for refinancing outstanding indebtedness by June 30

** HBIO says company faces substantial doubt about its ability to continue as going concern but expects available cash to finance operations while it works on credit agreement refinancing

** As of last close, HBIO down ~64% YTD

 (Reporting by Pritam Biswas in Bengaluru)

 ((Pritam.Biswas@thomsonreuters.com))